Core Viewpoint - The strategic cooperation agreement between China National Pharmaceutical Group's subsidiary, Zhongsheng Beikong Biotechnology, and Xiaoshou Medical aims to enhance grassroots medical services and resource allocation in China [1] Group 1: Strategic Cooperation - The agreement was signed on February 11, 2026, in Beijing, focusing on multi-dimensional collaboration in the grassroots medical field [1] - Xiaoshou Medical is a digital service provider for grassroots healthcare in China, connecting and empowering medical institutions through technology [1] - The partnership is expected to integrate quality R&D capabilities with digital channel resources, accelerating the penetration of products and services into grassroots medical institutions [1] Group 2: Company Background - Zhongsheng Beikong Biotechnology is a leading supplier of in vitro diagnostic reagents in China, engaged in R&D, production, sales, and distribution of diagnostic products [1] - The company provides reliable disease testing reagents to hospitals and healthcare institutions, aligning with national strategies for improving grassroots healthcare systems and the "Healthy China" initiative [1] Group 3: Xiaoshou Medical's Role - Xiaoshou Medical has established partnerships with thousands of grassroots medical institutions across all provinces in China [1] - The company has developed an AI digital platform that integrates medical institution information systems, serving as a core "connector" to enhance operational efficiency and accessibility of grassroots medical services [1]
中生北控生物科技(08247.HK)与广东小手医疗签署战略合作协议 共同推动优质医疗资源下沉及基层医疗服务能力提升